Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Cosentyx (secukinumab)
pCPA File Number:
20951
Negotiation Status:
Concluded with an LOI
Indication(s):
Psoriatic Arthritis
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CADTH Project Number:
SR0476-000
pCPA Engagement Letter Issued:
2017-04-13
Negotiation Process Concluded:
2017-12-19